Swiss-American eye care company Alcon Inc (NYSE:ALC) saw its stock drop after cutting its 2025 outlook due to increased tariff impact. The company anticipates a gross tariff impact of around $100 million, up from the previously expected $80 million. Second-quarter sales were $2.58 billion, missing the consensus of $2.63 billion.

Surgical net sales, which include implantables, consumables, and equipment/other, rose to $1.5 billion, a 2% increase on a reported basis and 1% on a constant currency basis. Implantables net sales decreased by 2%, while consumables net sales increased by 6%, and equipment/other net sales were down 1% in constant currency.

Vision Care net sales, including contact lenses and ocular health, reached $1.1 billion, up 6% on a reported basis and 5% on a constant currency basis. Contact lenses’ net sales rose by 9%, driven by product innovation, while ocular health net sales increased by 2%.

Alcon reported adjusted earnings of 76 cents per share, surpassing the consensus of 72 cents. The company’s operating margin in the second quarter was 9.6%, lower than last year’s 12.8%. CEO David J. Endicott expressed optimism about recent product launches driving momentum and long-term value for shareholders.

Alcon confirmed fiscal year 2025 adjusted earnings of $3.05-$3.15 versus the consensus of $3.12 but revised sales guidance to $10.3 billion-$10.4 billion from the previous $10.4 billion-$10.5 billion, below the consensus of $10.48 billion.

Read more at Yahoo Finance: Alcon Cites Tariffs And Soft Market In Lowered Sales Outlook, Shares Fall